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Supplementary Materials and Methods 
We analysed a total of 5 DNA methylation data sets (SI table S1).  
Precursor and cancer DNA methylation datasets: Our primary DNA methylation data sets 
focused on the profiling of precursor cancer lesions and are available from the GEO website 
(www.ncbi.nlm.gov/geo) under accession numbers GSE30758 and GSE69914.  
Dataset GSE30758 consists of 152 cytologically normal cervical smear samples, representing 
prospectively collected samples within the ARTISTIC trial, with 75 of the women who 
provided a sample developing a cervical intraepithelial neoplasia of grade 2 or higher 
(CIN2+) three years after sample collection [1].  In order to test whether CpGs identified 
from GSE30758, i.e. CpGs that correlate with the risk of CIN2+, show more progressive 
changes in CIN2+ and cervical cancer we used three other data sets (GSE20080, GSE37020, 
GSE30759) profiling normal cervical and CIN2+ or cervical cancer samples (SI table S1). 
All of these datasets were generated using Illumina Infinium 27k beadarrays and we used the 
normalized data, as described by us previously [1, 2]. 
Dataset GSE69914 was generated using Illumina Infinium 450k beadarrays and consists of 
50 normal breast tissue samples from healthy women, a set of 42 matched normal-adjacent 
breast cancer pairs (a total of 84 samples), and a further 263 unmatched breast cancers. Raw 
data was processed (intra-sample normalization) with minfi [3] and type-2 probe bias 
corrected using BMIQ [4]. Subsequently, we tested for batch effects by performing a SVD on 
the intra-sample normalized data matrix, and checking which factors (biological or technical) 
the top components of variation were correlating with. The top components of variation in 
this data matrix correlated with biological factors, notably normal-cancer status. 
 
 
Statistical algorithms for Differential Variability (DV) 
We compared a total of 5 algorithms/statistical tests, aimed at identifying differentially 
variable features. The five DV algorithms/tests are (i) Bartlett’s test [10], (ii) a novel DV 
algorithm, which we call “iEVORA” (similar to the original EVORA-Epigenetic Variable 
Outliers for Risk prediction Analysis algorithm [1, 2] ), (iii) a joint test for differential means 
and differential variance in DNA methylation (“J-DMDV”)[11], (iv) an empirical Bayes 
Levene-type test (“DiffVar”) [12] and (v) a test based on a generalized additive model for 
location and scale (“GAMLSS”) [13]. With the exception of iEVORA, which we present here 
for the first time, all other DV algorithms (i.e. BT/EVORA, J-DMDV, DiffVar, GAMLSS) 
have been previously used in cancer epigenome or EWAS studies [1, 13, 14]. 
BT & iEVORA: Briefly, Bartlett’s test (BT) is similar to an F-test for testing 
homoscedasticity, and is well-known to be sensitive to single outliers. Because of this, we 
also consider a regularized version of it, which we call iEVORA, whereby features deemed 
significant by Bartlett’s test are re-ranked according to an ordinary differential methylation 
statistic (e.g. the statistic from a t-test). Thus, in iEVORA, significance is assessed at the level 
of differential variability using Bartlett’s test, but significant DV features with larger changes 
in the average DNA methylation are favored over those with smaller shifts in average DNA 
methylation. This re-ranking strategy therefore ensures that DV features driven by single, or a 
few, outliers are only ranked highly if there are no features which are differentially 
methylated in terms of mean DNAm levels.   
J-DMDV, DiffVar and GAMLSS: The third algorithm (”J-DMDV”), proposed by Wang and 
Ahn [11], works in the M-value (M=log2[β/(1-β)] basis and uses a joint score test for mean 
and variance within a linear regression framework. The fourth algorithm (“DiffVar”) is based 
on an empirical Bayes extension of the Levene-test [12]. Briefly, this algorithm first 
computes the square (or absolute) deviations of samples within a phenotype from the 
corresponding group (phenotype) mean using the M-value basis. It then uses the framework 
of moderated t-tests [15], to compare the distribution of deviations between the two 
phenotypes.  The final algorithm (“GAMLSS”) was developed by Wahl et al [13] within the 
GAMLSS (Generalized Additive Models for Location, Scale and Shape) framework. This 
algorithm also works in the M-value basis, and here we adapt it to run on 3 separate 
generalized linear additive models within a nested framework: a null model without mean 
and variance, a regression model for the mean only and a model for the mean and variance. 
Two likelihood ratio tests are then constructed by comparing the log-likelihoods of the mean-
only model to the null, and the mean+variance model to the mean-only model. This yields 
two P-values for each feature, and features are deemed significant if at least one of these two 
P-values is less than a nominal threshold (after adjustment for multiple testing). Thus, 
GAMLSS will yield significant hits if there are differences in terms of mean DNAm. We also 
note that our implementation of GAMLSS does not compare a variance-only model to the 
null, since the algorithm aims to identify additional features where variance “adds predictive 
value” over a model which only includes the mean. 
 
Evaluation of DV algorithms to detect true DVCs on simulated data 
In order to compare the DV algorithms to each other, we devised a simulation framework 
allowing for different types of differential variability. In each simulation run we generated an 
artificial DNA methylation data matrix consisting of 6000 CpGs and 100 samples. Samples 
were subdivided into two phenotypes, a “normal” and a “disease state”, each comprising 50 
samples. We declared 600 CpGs to be truly differentially variable, allowing for 3 different 
types of DV, with 200 CpGs in each type. The remaining 5400 CpGs are not differentially 
variable. These are modelled from a beta-value distribution B(a1,b1) with a1=10 and b1=90, 
i.e. we assume that these CpGs are generally unmethylated with a mean beta value of 0.1, 
with a standard deviation of approximately +/- 0.03. For the 600 true positives, a proportion 
of the samples in the “disease” phenotype are modelled from a beta-value distribution 
B(a2,b2) with a2=6 and b2=4, i.e. a distribution with mean value 0.6 and a standard 
deviation of approximately +/- 0.15. We note that although in this simulation we consider all 
CpGs to be unmethylated in the normal state, that there is no loss of generality, since 
mathematically, there is a complete symmetry between unmethylated and methylated CpGs. 
Thus, for the 600 true DVCs and for a number of samples in the disease phenotype, there will 
be an average increase in DNAm of ~0.5. The 600 true DVCs however fall into 3 categories 
of DV. For 200 of these CpGs, we model all samples in the disease phenotype from B(a2,b2). 
Thus, these DVCs will typically also differ in terms of the mean level of DNA methylation 
and in fact, will exhibit stronger differences in terms of the mean DNAm than in terms of 
differential variance. Hence, these 200 DVCs are of “type-1a” DV. For another 200 CpGs, 
we only allow 20 of the 50 disease phenotype samples to be modelled from B(a2,b2), with 
rest of the samples being modelled from B(a1,b1).  Thus, for these DVCs, half of the disease 
samples exhibit increases in DNAm, with the rest being indistinguishable from the normal 
phenotype. For these CpGs, differential variance is the key discriminatory characteristic, 
although they will still exhibit significant differences in terms of mean DNAm since a 
reasonable fraction of the disease samples exhibit deviations from the normal state. These 
DVCs are of “type-1b” differential variability. Finally, for the last set of 200 true positives, 
we only allow 3 disease samples to differ from the normal state. For these DVCs, there is 
therefore no significant difference in terms of the average DNA methylation between the two 
phenotypes. However, the variance will differ owing to the outliers in the disease phenotype. 
These DVCs are defined as being of “type-2”. 
We performed a total of 100 Monte Carlo runs, in each run recording 5 performance 
measures for each of the five DV algorithms: (1) the overall sensitivity of the DV algorithm 
using an FDR (false discover rate) corrected threshold of 0.05, (2) the true FDR at the 
estimated FDR < 0.05 threshold where the FDR estimate was obtained using Q-values [16], 
(3-5) the sensitivities to detect type-1a, type-1b and type-2 differentially variable CpGs. We 
focused on the FDR and not the FPR (false positive rate), since it is the FDR which gives us 
the confidence level that a given positive is a true positive, i.e. the FDR is related to the 
positive predictive value (PPV) through the relation FDR=1-PPV. 
 
Evaluation of DV algorithms on real DNA methylation data 
Initially, we compared the algorithms in their ability to detect DVCs between normal samples 
from healthy women and normal samples from women who developed neoplasia or who had 
cancer (see section on DNAm data sets for details), without considering the likelihood of 
these DVCs being true positives. Thus, for each of the DV algorithms and each CpG site, we 
estimated P-values, and from these, Q-values (FDR) [16]. In the case of BT and iEVORA, P-
values came from Bartlett’s test. In the case of DiffVar and J-DMDV, both tests provide P-
values, as described in the respective publications. Features were deemed significant if 
Q<0.05. In the case of GAMLSS, we obtained two P-values, one assessing whether the mean 
is associated with the phenotype, and another assessing whether the variance adds predictive 
value over the mean. Both sets of P-values were transformed into Q-values and features with 
at least one of these Q-values being less than 0.05, were selected and deemed statistically 
significant. 
To enable a more formal comparison of the DV algorithms, we devised a strategy that would 
allow us to estimate the positive predictive value (PPV) of the test. The key insight or 
hypothesis is that DVCs obtained from the previous step are more likely to be biological true 
positives if they exhibit progressive changes in DNA methylation in either neoplastic or 
invasive cancer tissue. A feature detected in pre-neoplastic lesions that is biological relevant 
is more likely to mark cells which become neoplastic and therefore one would expect 
enrichment of these marks in neoplasia and invasive cancer. This means that if a given “true 
positive” CpG site exhibits higher DNAm levels (maybe only marginally so) in precursor 
cancer lesions, that this same site will undergo larger and more frequent changes in DNAm 
when the cells are neoplastic or invasive. Statistically, this “progression effect” can be 
measured using t-statistics from a t-test, since the t-statistic is proportional to the average 
deviation in DNAm from the normal state. A similar argument can be applied to the case of 
CpG sites that undergo marginal hypomethylation in precursor cancer lesions. 
In the context of cervical carcinogenesis, we thus applied the DV algorithms to identify 
DVCs hypervariable in the 75 normal samples which 3 years later progressed to CIN2+ status 
compared to the 77 normal samples from women remained healthy (the “ART” data set in SI 
table S1). The DNAm data for this set were generated on Illumina 27k beadarrays, and so, 
because of the design of the 27k array, we only focused on DVCs which exhibited increases 
in DNAm in the precursor lesions. We considered the top ranked 500, 1000 and 5000 DVCs 
(irrespective of FDR values attaining statistical significance). In the case of GAMLSS, which 
provides two P-values per feature, we ranked the selected features according to the 
significance of the DV statistic. In each case, we then computed and compared t-statistics of 
these top ranked DVCs in two independent Illumina 27k data sets profiling normal and 
CIN2+ samples, and another 27k dataset of normal cervix and cervical cancers 
(“CIN2+(A)&(B)” and “CC” in SI table S1). The fraction of DVCs attaining t-statistics 
larger than 1.96 (P<0.05) and preserving the same directionality of change in the independent 
data was used as the PPV estimate. 
In the context of breast carcinogenesis, we applied the DV algorithms to identify DVCs 
hypervariable in the 42 normal-adjacent samples compared to the 50 normal samples from 
healthy women. Because of the design of the 450k array, we now considered DVCs which 
exhibited either increases or decreases in DNAm in the normal-adjacent samples. We 
considered the top ranked 500, 1000 and 5000 DVCs in each category (irrespective of FDR 
values attaining statistical significance). In each case, we then computed t-statistics of these 
top ranked CpGs, as derived from comparing the 50 normal breast tissue samples to 305 
breast cancers. The fraction of DVCs attaining t-statistics larger (lower) than 1.96 ( -1.96) 
(P<0.05) and preserving the same directionality of change in the independent data, was used 
as the PPV estimate. 
 
Supplementary Figures 
 
fig.S1: t-statistics of DMCs (t-tests) and DVCs (for DV algorithms), selected from the 
ARTISTIC cohort, in two independent data sets, one profiling 24 normal cervical smears (N) 
and 24 CIN2+ samples (left panels), and another profiling 15 normal cervical tissue (N) and 
48 invasive cervical cancers (CC) (right panels). CpGs were selected from the ARTISTIC 
data set (comparing 75 normal cervical smear samples from women who 3 years later 
developed a CIN2+ to 77 from women who remained disease free) according to one of the 6 
feature selection algorithms. Because of the design of the 27k beadarray, only CpGs 
hypermethylated in the prospective CIN2+ samples were considered. Top panels are for the 
top ranked 500 CpGs, middle panels for the top rank 1000 CpGs, lower panels for the top 
ranked 5000. In the panels, those CpGs exhibiting progression should have positive t-
statistics, and thus we see that CpGs selected and ranked using iEVORA generally do show 
more consistent progressive changes. 
 
 
 
fig.S2: t-statistics of DMCs (t-tests) and DVCs (for DV algorithms), selected from the 
ARTISTIC cohort,  in another independent data set, profiling 30 normal cervical smears (N) 
and 18 CIN2+ samples. Further details as in fig.S3. 
 
 
 
 
 
 
 fig.S3: t-statistics of CpGs, selected using one of the 6 feature selection algorithms  from 
comparing 50 normal breast samples (N) to 42 normal samples collected adjacent (NADJ) to 
breast cancers, with the t-statistics computed by comparing the 50 normal breast samples to 
305 breast cancers (BC). Hypermethylated and hypomethylated CpGs were ranked 
separately, using one of the 6 different algorithms, as indicated. Panels are for the top ranked 
500, 1000 and 5000 CpGs. In the left panels, those CpGs exhibiting progressive 
hypermethylation should have positive t-statistics, whereas those in the right panels showing 
progressive hypomethylation should have negative t-statistics, and thus we see that DVCs 
selected and ranked using iEVORA generally show the most consistent progressive changes. 
 
 fig.S4: Real data examples of different types of DV in breast carcinogenesis involving 
hypomethylation in the disease state. The horizontal dashed lines indicate the mean in each 
phenotype. Phenotype is labelled by a different color. N=normal, NADJ=normal breast tissue 
adjacent to a cancer, BC=breast cancer. P-values from a t-test (TT), a Wilcoxon rank sum test 
(WT) and Bartlett’s test (BT) are given. Bartlett’s test is a test for differential variance. 
 
 
fig.S5:  Progression of DV in breast carcinogenesis. Left panel depicts the DNAm fraction 
of a specific CpG (cg24189904) across 3 different disease stages in breast carcinogenesis, 
including normal cells (N), normal cells adjacent to a breast cancer (N-ADJ) and breast 
cancer (BC). Right panel is a boxplot representation, indicating the P-values from a t-test 
(TT), Wilcoxon rank sum test (WT) and Bartlett’s test (BT) between the normal state and 
each of N-ADJ and BC.    
 
 
 
 
 
 
  
 
 
 
 
 
 
Supplementary Tables 
Dataset Total number 
of samples 
Tissue 
type 
Phenotypes Accession 
ART 152 Cervix 75 preCIN2+ and 77 normal GSE30758 
CIN2+(A) 48 Cervix 24 normal and 24 CIN2+ (all HPV+) GSE37020  
CIN2+(B) 48 Cervix 30 normal + 18 CIN2+ GSE20080 
CC 63 Cervix 15 normal + 48 cervical cancers GSE30759 
PREBC 397 Breast 50 normals + 42 matched normal-
tumor pairs (84) + 263 unmatched 
tumors 
GSE69914 
 
table S1- Datasets used in this study. Table lists details of the 5 DNA methylation datasets 
considered in this work. We provide the name of the cohort/study, the total of number of 
samples used, the tissue/cell-type, the distribution of samples according to the various 
phenotypes and finally the data accession number. 
 
 
TF ChIP-Seq experiment OR(dvUPdmUP) P(dvUPdmUP) OR(dvUPdmDN) P(dvUPdmDN) 
EZH2_39875_None__Broad 6.22 < 1E-100 0.03 1 
RBBP5_A300.109A_None__Broad 2.06 9.00E-54 0.01 1 
SUZ12_None__USC 4.89 4.00E-44 0.26 0.996 
CTCF_None__Broad 2.29 2.00E-33 0.33 1 
Rad21_None__Stanford 2.49 2.00E-33 0.17 1 
CTCF_None__UT.A 2.61 3.00E-33 0.27 1 
CtBP2_None__USC 2.37 2.00E-32 0.03 1 
Rad21_None__HudsonAlpha 2.24 5.00E-32 0.27 1 
CTCF_SC.5916_None__HudsonAlpha 2.36 2.00E-28 0.24 1 
Znf143_16618.1.AP_None__Stanford 1.94 5.00E-24 0.1 1 
NRSF_None__HudsonAlpha 2.47 5.00E-14 0.09 1 
SIN3A_NB600.1263_None__Stanford 1.45 2.00E-13 0.01 1 
CHD1_A301.218A_None__Broad 1.84 3.00E-13 0.07 1 
TBP_None__Stanford 1.48 8.00E-13 0.02 1 
Max_None__USC 1.72 6.00E-11 0.03 1 
GABP_None__HudsonAlpha 1.77 6.00E-10 0.04 1 
TAF1_None__HudsonAlpha 1.36 7.00E-10 0.01 1 
Bach1_sc.14700_None__Stanford 1.67 2.00E-09 0.03 1 
Egr.1_None__HudsonAlpha 1.65 3.00E-09 0.03 1 
TEAD4_SC.101184_None__HudsonAlpha 1.75 2.00E-08 0.1 1 
HDAC2_SC.6296_None__HudsonAlpha 1.76 1.00E-05 0 1 
YY1_SC.281_None__HudsonAlpha 1.35 3.00E-05 0.09 1 
TAF7_SC.101167_None__HudsonAlpha 1.33 5.00E-05 0.02 1 
USF.1_None__HudsonAlpha 1.41 1.00E-04 0.07 1 
Mxi1_AF4185_None__Stanford 1.36 4.00E-04 0 1 
USF2_None__Stanford 1.45 0.001 0.06 1 
Sin3Ak.20_None__HudsonAlpha 1.3 0.001 0 1 
ATF2_SC.81188_None__HudsonAlpha 1.33 0.002 0.04 1 
JunD_None__Stanford 1.37 0.002 0 1 
SP4_V.20_None__HudsonAlpha 1.24 0.002 0 1 
MafK_ab50322_None__Stanford 1.72 0.003 0.18 0.996 
TCF12_None__HudsonAlpha 1.45 0.006 0.18 1 
JunD_None__HudsonAlpha 1.31 0.008 0 1 
p300_None__HudsonAlpha 1.28 0.009 0.04 1 
SP1_None__HudsonAlpha 1.19 0.013 0 1 
c.Myc_None__UT.A 2.28 0.015 1.61 0.353 
Pol2_None__HudsonAlpha 1.11 0.025 0.02 1 
GTF2F1_AB28179_None__Stanford 1.21 0.036 0 1 
NANOG_SC.33759_None__HudsonAlpha 1.41 0.059 0 1 
CHD1_A301.218A_None__Stanford 1.27 0.073 0.2 0.999 
RFX5_200.401.194_None__Stanford 1.36 0.082 0 1 
Nrf1_None__Stanford 1.17 0.094 0 1 
CHD2_AB68301_None__Stanford 1.12 0.109 0 1 
Pol2.4H8_None__HudsonAlpha 1.08 0.112 0.04 1 
SRF_None__HudsonAlpha 1.18 0.152 0 1 
c.Jun_None__Stanford 1.31 0.16 0 1 
c.Myc_None__Stanford 1.13 0.17 0 1 
BCL11A_None__HudsonAlpha 1.69 0.179 0 1 
FOSL1_SC.183_None__HudsonAlpha 1.24 0.262 0.34 0.948 
RXRA_None__HudsonAlpha 1.14 0.407 0 1 
Pol2_None__UT.A 1.02 0.408 0.01 1 
ATF3_None__HudsonAlpha 0.99 0.552 0 1 
SP2_SC.643_None__HudsonAlpha 0.95 0.658 0.06 1 
CEBPB_None__Stanford 0.93 0.686 0 1 
POU5F1_SC.9081_None__HudsonAlpha 0.8 0.759 0.95 0.621 
SIX5_None__HudsonAlpha 0.9 0.772 0 1 
BRCA1_A300.000A_None__Stanford 0.81 0.894 0 1 
JARID1A_ab26049_None__Broad 0.4 1 0 1 
 
table S2: Odds Ratio (OR) and one-tailed Fisher-test P-values of enrichment of 58 TF ChIP-
Seq binding sites, as determined in hESCs, among two classes of DVCs identified using 
iEVORA comparing normal breast tissue from healthy women to normal tissue adjacent to 
breast cancers: hypervariable + hypermethylated (dvUPdmUP) and hypervariable + 
hypomethylated (dvUPdmDN). 
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